1. Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawi
- Author
-
Scott A. Nabity, Kelvin Mponda, Steve Gutreuter, Diya Surie, Anne Williams, Andrea J. Sharma, Elizabeth R. Schnaubelt, Rebekah E. Marshall, Hannah L. Kirking, Suzgo B. Zimba, Joram L. Sunguti, Laphiod Chisuwo, Mabvuto J. Chiwaula, Jesse F. Gregory, Robin da Silva, Michael Odo, Andreas Jahn, Thokozani Kalua, Rose Nyirenda, Belaineh Girma, James Mpunga, Nicole Buono, Alice Maida, Evelyn J. Kim, Laurence J. Gunde, Tigest F. Mekonnen, Andrew F. Auld, Adamson S. Muula, and John E. Oeltmann
- Subjects
isoniazid ,tuberculosis preventive treatment ,tuberulosis ,human immuno defficiency virus (HIV) ,pellagra ,niacin (nicotinic acid) ,Public aspects of medicine ,RA1-1270 - Abstract
Background: Pellagra is caused by niacin (vitamin B3) deficiency and manifested by a distinctive dermatitis. Isoniazid is critical for treating tuberculosis globally and is a component of most regimens to prevent tuberculosis. Isoniazid may contribute to pellagra by disrupting intracellular niacin synthesis. In 2017, Malawian clinicians recognized a high incidence of pellagra-like rashes after scale-up of isoniazid preventive treatment (IPT) to people living with HIV (PLHIV). This increase in pellagra incidence among PLHIV coincided with a seasonal period of sustained food insecurity in the region, which obscured epidemiological interpretations. Although isoniazid has been implicated as a secondary cause of pellagra for decades, no hypothesis-driven epidemiological study has assessed this relationship in a population exposed to isoniazid. We developed this case-control protocol to assess the association between large-scale isoniazid distribution and pellagra in Malawi.Methods: We measure the relative odds of having pellagra among isoniazid-exposed people compared to those without exposure while controlling for other pellagra risk factors. Secondary aims include measuring time from isoniazid initiation to onset of dermatitis, comparing niacin metabolites 1-methylnicotinamide (1-MN), and l-methyl-2-pyridone-5-carboxamide (2-PYR) in urine as a proxy for total body niacin status among subpopulations, and describing clinical outcomes after 30-days multi-B vitamin (containing 300 mg nicotinamide daily) therapy and isoniazid cessation (if exposed). We aim to enroll 197 participants with pellagra and 788 age- and sex-matched controls (1:4 ratio) presenting at three dermatology clinics. Four randomly selected community clinics within 3–25 km of designated dermatology clinics will refer persons with pellagra-like symptoms to one of the study enrollment sites for diagnosis. Trained study dermatologists will conduct a detailed exposure questionnaire and perform anthropometric measurements. A subset of enrollees will provide a casual urine specimen for niacin metabolites quantification and/or point-of-care isoniazid detection to confirm whether participants recently ingested isoniazid. We will use conditional logistic regression, matching age and sex, to estimate odds ratios for the primary study aim.Discussion: The results of this study will inform the programmatic scale-up of isoniazid-containing regimens to prevent tuberculosis.
- Published
- 2020
- Full Text
- View/download PDF